Preoperative Condition in Giant Obese Patients

NCT02616003 on ClinicalTrials.gov · last registry update 2021-03-23

Finished January 2018, after enrolling 50 people. Primary outcome, as filed: Operability. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Sana Klinikum Offenbach
Sponsor type: Other
Enrollment: 50
Started: 2014-04
Primary completion: 2018-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Operability

Conditions studied

Morbid Obesity · Bariatric Surgery Candidate

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.